Published On : September 2026
A buyer comparing DEL screening providers purely by library size is skipping the distinction that actually narrows the field first: screening technology.
Within the cellular DNA-encoded library screening market, screening technology, cellular, live cell-based, phenotypic, target-based, affinity selection or covalent, is the specification decided first, since which of these six approaches a discovery program uses determines which chemistry platforms and library designs are even viable before target class or therapeutic application is considered.
This page describes six screening technology categories and five DEL chemistry platform categories strictly as market segments.
It provides no wet-lab protocol, assay-development or DNA-tag-decoding guidance, and makes no claim about hit rate, hit validation success rate or comparative screening performance for any technology category.
A program built around cellular DEL screening generally requires a different library design and readout approach than one built around affinity selection DEL screening, regardless of which target class or therapeutic application it is ultimately aimed at.
That is why discovery program leaders experienced in this market lead provider conversations with screening technology rather than with library size or chemistry platform preference alone.
Five DEL chemistry platform categories complete the specification once screening technology is settled, spanning DNA-encoded small molecule libraries, macrocyclic DEL platforms, peptide-based DEL platforms, DNA-templated chemistry platforms and proprietary encoded chemistry platforms.
For buyers, establishing which screening technology a program requires is the starting point for any DEL screening provider conversation.
For providers, screening technology and chemistry platform breadth across all six and five categories respectively widens the addressable share of any discovery partner's program requirements.
Buyers who skip this distinction risk shortlisting a provider whose screening technology is poorly matched to their target class, only to discover the mismatch during pilot validation rather than at the initial specification stage.
Screening technology also interacts with sales cycle length, since a program built around a newer, less established technology such as covalent DEL screening typically requires a longer scientific assessment period than a program built around an established affinity selection approach.
Cellular DEL screening and live cell-based DEL screening form two closely related screening technology categories tracked in this report, both named here as market categories, with this page stating nothing about how either screening approach is actually run in the laboratory.
Cellular DEL screening applies DNA-encoded library chemistry within a cellular context rather than a purely biochemical one, which several discovery teams favor for targets whose relevant biology is difficult to reconstitute in a simplified biochemical assay.
Live cell-based DEL screening extends this further by running the screen against intact, living cells, an approach generally associated with targets where cellular context, membrane environment or intracellular localization materially shapes which molecules can engage the target at all.
Both categories sit alongside phenotypic DEL screening as approaches that incorporate more biological context than a purely target-based or affinity selection screen, without this page making any claim about which approach identifies more or better hits for any specific target.
Buyers pursuing translational research programs frequently favor cellular or live cell-based approaches specifically because these technologies preserve more of the biological signaling context that a purely biochemical assay would otherwise strip away.
Neither approach is presented in this report as superior to the other; the appropriate choice depends on the target class and discovery stage a given program has reached.
|
TECHNOLOGY WATCH Cellular DEL screening is the fastest-growing screening technology category tracked in this report, reflecting rising discovery-team interest in approaches that preserve more of a target's native biological context than purely biochemical screening methods. |
Phenotypic DEL screening and target-based DEL screening represent two different starting points for a DEL screening program: one anchored in an observable cellular outcome, the other anchored in a defined, already-identified molecular target.
Phenotypic DEL screening is generally selected when a discovery team wants to identify molecules that produce a desired cellular effect without first needing to know which specific target mediates that effect, useful for target classes where the relevant biology is not yet fully mapped.
Target-based DEL screening is generally selected once a specific target, such as a defined kinase or GPCR, has already been identified, letting the screen focus directly on molecules that engage that target.
Discovery stage relevance also varies by screening technology, since which discovery stages each screening technology supports differs meaningfully between phenotypic and target-based approaches: phenotypic screening more often supports earlier target identification work, while target-based screening more often supports later hit discovery and hit validation stages against an already-defined target.
For buyers, choosing between phenotypic and target-based DEL screening is a program-specific determination made in conjunction with how well a target's underlying biology is already understood.
Hit discovery timelines under a phenotypic approach can differ from those under a target-based approach, since phenotypic screening often requires an additional target-deconvolution step once a promising molecule is identified.
Affinity selection DEL screening and covalent DEL screening complete the screening technology dimension tracked in this report, both named here strictly as market categories with no claim made about the binding behavior or biological outcome either approach actually produces.
Affinity selection DEL screening is the largest screening technology category tracked in this report by discovery partnership volume, reflecting its established position as the most widely adopted DEL screening approach among current buyers.
Covalent DEL screening is generally associated with programs seeking molecules that engage a target through a covalent rather than reversible binding mode, a narrower but scientifically distinct screening technology category relative to the other five tracked in this report.
Commercially, affinity selection programs generally involve a broader base of established providers than covalent DEL screening, given how long affinity selection has been a mainstream DEL screening approach relative to more specialized covalent programs.
For providers, offering both affinity selection and covalent DEL screening widens addressable scope across discovery partners with different target-engagement requirements.
Providers offering covalent DEL screening alongside the more established affinity selection approach are generally positioning themselves for buyers whose target class specifically calls for a covalent engagement strategy, such as certain kinase or protease programs.
DNA-encoded small molecule libraries and macrocyclic DEL platforms represent two of the five chemistry platform categories tracked in this report, each defining a different chemical space that a given screening technology is run against.
DNA-encoded small molecule libraries are the most established chemistry platform category, generally offering the largest available library sizes among the platforms tracked in this report.
Macrocyclic DEL platforms build larger, more structurally constrained molecules than typical small molecule libraries, an approach several providers position for target classes such as protein-protein interactions where a larger binding interface can be advantageous.
Chemistry platform choice intersects closely with target class, since macrocyclic platforms are more frequently paired with structurally demanding target classes while small molecule libraries remain the default starting point across most target classes tracked in this report.
Buyers evaluating chemistry platform breadth generally look for a provider whose library covers both platforms, rather than committing early to a single chemistry format before target class requirements are fully understood.
Peptide-based DEL platforms, DNA-templated chemistry platforms and proprietary encoded chemistry platforms complete the chemistry platform dimension tracked in this report.
Peptide-based DEL platforms build libraries around peptide chemistry rather than small molecule or macrocyclic scaffolds, an approach some providers favor for target classes where peptide-like binding modes are more readily accessible.
DNA-templated chemistry platforms use the DNA scaffold itself to direct library synthesis chemistry, a technically distinct approach from libraries where DNA serves purely as an identification tag rather than a synthesis-directing template.
Proprietary encoded chemistry platforms cover provider-specific chemistry approaches that do not fit neatly into the four other categories, reflecting the degree of platform differentiation that exists across established DEL screening providers.
Chemistry platform relevance also varies by therapeutic focus, since the therapeutic applications each chemistry platform serves differ across these five categories, and this report's therapeutic application and end user segmentation sets out how that connection maps across the seven application categories this report tracks.
For buyers, confirming a provider's chemistry platform range early generally avoids mismatched library-diversity assumptions later in a program's scientific assessment stage.
Providers offering proprietary encoded chemistry platforms alongside the four more standardized categories generally differentiate on library diversity and scientific expertise, since chemistry platform economics sit outside what this page discusses.
This report tracks six screening technology categories used in cellular DNA-encoded library screening: cellular DEL screening, live cell-based DEL screening, phenotypic DEL screening, target-based DEL screening, affinity selection DEL screening and covalent DEL screening.
Cellular DEL screening applies DNA-encoded library chemistry within a cellular context, while affinity selection DEL screening is a more established, typically biochemical approach and the largest screening technology category tracked in this report by discovery partnership volume.
This report tracks five DEL chemistry platform categories: DNA-encoded small molecule libraries, macrocyclic DEL platforms, peptide-based DEL platforms, DNA-templated chemistry platforms and proprietary encoded chemistry platforms.
Screening technology determines which chemistry platforms and library designs are viable for a given program before target class or therapeutic application is even considered, which is why this page treats screening technology as the first specification decision rather than chemistry platform.
No. Live cell-based DEL screening runs the screen against intact living cells, while phenotypic DEL screening is defined by identifying molecules that produce a desired cellular outcome; the two approaches often overlap in practice but are tracked as distinct categories in this report.